GlobeNewswire by notified

Multi-omics service provider Sequanta completes extended concordance validation of Olink® Target 48/96 and Olink® Explore

Share

UPPSALA, Sweden, September 15, 2022 , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China, successfully completed extended concordance testing on Olink’s platforms (Olink® Target 48/96 and Olink® Explore), fulfilling specific requirements that supplement the Olink quality acceptance criteria. This latest validation was initiated by and implemented in cooperation with a leading global pharmaceutical company.

In meeting this standard of excellence, Sequanta is the first service provider in China to pass extended concordance testing, fulfilling the rigorous quality requirements expected by multi-national pharmaceutical companies. This helps ensure that both global and local pharmaceutical customers have access to high quality Olink proteomic data that supports their drug development processes. Due to regulations that may restrict sending human blood samples abroad, world-class local service providers are necessary to perform analysis of human samples in country.

“This extended concordance validation enables global and local pharmaceutical companies to broaden their activities in China and support their local clinical studies by proteomics measurements. This validation ensures that such capabilities are put in place domestically in China.” said Andrea Ballagi, MD, PhD, Vice President Sales and Marketing Asia Pacific Region, Olink Proteomics. “We are proud to have Sequanta as our first partner lab in China, and to translate our philosophy of serving the global protein biomarker research market into action. Generation of high-quality data and delivering scientific innovation with a clear understanding of customer needs are key pillars of success.”

Since 2021, Sequanta and Olink's partnership has provided Sequanta access to Olink® Proximity Extension Assay (PEA) technology. This collaboration has enabled end-to-end multi-omic clinical studies, which could also facilitate the development of precision medicine in China. As one of Olink’s preferred third-party service providers in China, Sequanta is serving pharmaceutical and academic customers in this geography, utilizing Olink’s innovative and disruptive technology, particularly in high-throughput multi-omics research based on genomics, transcriptomics, and proteomics.

“This is a new milestone achieved by Olink and Sequanta after the two companies announced a strategic partnership to serve pharma and academia in China. Big congratulations to both teams who have spent significant efforts in completing the concordance validation”, said Lele Sun, PhD, Founder and CEO at Sequanta. "This evaluation not only ensures that Sequanta offers Olink® Target 48/96 and Olink® Explore panels that are as stable and accurate as other Olink labs worldwide, but also shows our persistence in pursuing high quality data and excellent operational management, which differentiates us from other providers in the market.”

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

About
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About Sequanta
Sequanta Technologies is a leading multi-omics research and clinical service provider in China, focusing on genomics, proteomics and related services to support pharmaceutical clients in biomarker discovery and clinical trials. Sequanta provides diversified genomics and proteomics assays validated by research standard and CAP standard, which include genotyping and gene expression qPCR assays, NGS assays and protein biomarker detection assays. The featured assays include Foundation One CDx, Illumina TSO500 assay for tissue and ctDNA, 10x Genomics single cell solution, Olink Target 96 QPCR, Olink Explore 384/1536/3072 panel on NovaSeq, meta-genome NGS, mRNA sequencing, smRNA sequencing, whole genome sequencing, exome sequencing, etc. Customized panels are also available based on specific project needs.

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Automox Expands Functionality and Reach with Remote Control and New Global Partnership4.10.2022 15:00:00 CEST | Press release

Product and distribution momentum set to fuel international growth Boulder, Colo, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Automox®, the cloud-native IT operations provider, today announced general availability of its remote control feature, offering global IT teams advanced troubleshooting capabilities from a single cloud-native console. Remote control is a powerful tool for IT teams everywhere. IT administrators often face a mountain of device-related issues daily, ranging from email account errors, password resets, and devices that won’t update, to processes that drain device resources. Without the ability to perform an in-depth investigation directly on the device, providing a fix generally requires significant time from IT teams and multiple tools. With remote control, IT admins can gain immediate access to end-user devices to troubleshoot issues directly. The functionality was developed in-house by Automox’s product team to help IT teams quickly address a wide array of common endpoint i

Huhtamaki launches innovative, recyclable ice cream packaging solution in the US, made with 95% renewable biobased material4.10.2022 15:00:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 04.10.2022 AT 16.00 EEST Huhtamaki launchesinnovative, recyclableice cream packaging solution in the US, made with 95% renewable biobased material Paper-based technology allows packaging to enter the North American paper recycling system easily.ConnectedPackaging QR code provides consumers with more information on sustainability. Huhtamaki, a key global provider of sustainable packaging solutions, today launches ICON® packaging, a breakthrough paper technology, initially for use for ice cream containers and lids, which enables recycling in communities with paper product recycling programs across the United States. This is a significant breakthrough in delivering a sustainable solution for consumers which combines Huhtamaki’s proprietary water-based barrier coating with SFI-certified paperboard and results in the entire package being made with 95% renewable biobased material. This enables the ice cream containers and lids to be recycled along with other paper

Tilray Medical Relaunches Cannabis Oral Solution Across Ireland4.10.2022 13:00:00 CEST | Press release

Tilray’s Medical Cannabis Product Now Available and Reimbursed Under Ireland’s Medical Cannabis Access Program LEAMINGTON, Ontario and CANTANHEDE, Portugal, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that it has successfully relaunched its EU GMP-produced medical cannabis oral solution in Ireland under the country’s Medical Cannabis Access Program (MCAP). Tilray’s approved product has also recently received reimbursement approval, which gives patients cost reimbursement and ensures more eligible patients can access quality medical cannabis under Ireland’s MCAP. Denise Faltischek, Tilray Brands’ Chief Strategy Officer and Head of International Business, said, “We are extremely proud to relaunch in Ireland with an expanded footprint. The MCAP reimbursement approval is a tremendous step in providi

Moore Nanotechnology Systems Opens Global Training and Process Development Center in Charlotte, North Carolina4.10.2022 13:00:00 CEST | Press release

SWANZEY, N.H., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Moore Nanotechnology Systems (“Nanotech”), a leading global supplier of ultra-precision machining systems, announces the grand opening of their Global Training and Process Development Center in Charlotte, North Carolina. Mark Boomgarden, President and CEO of Nanotech shared, “Nanotech is very excited to announce the grand opening of our Global Training and Process Development Center in Charlotte, North Carolina. Although the initial focus of this facility is to provide customer-specific training and industry-leading process development, it also provides Nanotech incremental production capacity to meet the demands of a rapidly growing market.” Nanotech purchased and recently completed the upfit of a 50,000 ft2 building located in the Northpark Corporate Park - Charlotte, NC. Nanotech’s core technology and employee base is in Swanzey, New Hampshire, and this foundation is fundamental to the products and services in which they provide. But

FRO - Changes to the Board composition4.10.2022 08:06:57 CEST | Press release

Frontline Ltd. (“Frontline” or “the Company”) announces the appointment of Mr. Marios Demetriades as a Director of the Company. Marios Demetriades is an experienced Financial Services professional with significant experience as a Non-Executive Director in various listed and private companies in the Banking, Infrastructure and Shipping industries. He previously served as the Minister of Transport, Communications and Works for the Republic of Cyprus from 2014 to 2018 and held various positions in the Accounting, Investment and Banking sectors. He is a qualified Chartered Accountant and Chartered Financial Analyst holder and a member of the CFA Institute, the Institute of Chartered Accountants in England and Wales and the Institute of Certified Public Accountants of Cyprus (ICPAC). Mr. Demetriades is a Cypriot citizen and resides in Cyprus. October 4, 2022 The Board of Directors Frontline Ltd. Hamilton, Bermuda Questions should be directed to: Lars H. Barstad, Chief Executive Officer, Fro